Edition:
India

FibroGen Inc (FGEN.OQ)

FGEN.OQ on NASDAQ Stock Exchange Global Select Market

45.76USD
19 Oct 2020
Change (% chg)

$-0.36 (-0.78%)
Prev Close
$46.12
Open
$46.40
Day's High
$46.72
Day's Low
$45.49
Volume
219,552
Avg. Vol
295,444
52-wk High
$51.00
52-wk Low
$22.65

Latest Key Developments (Source: Significant Developments)

Fibrogen Reports Second Quarter 2020 Financial Results
Friday, 7 Aug 2020 

Aug 6 (Reuters) - FibroGen Inc ::FIBROGEN REPORTS SECOND QUARTER 2020 FINANCIAL RESULTS.Q2 LOSS PER SHARE $0.95.Q2 REVENUE $42.9 MILLION VERSUS $191.6 MILLION.Q2 REVENUE ESTIMATE $33.8 MILLION -- REFINITIV IBES DATA.Q2 EARNINGS PER SHARE ESTIMATE $-0.64 -- REFINITIV IBES DATA.FIBROGEN- REITERATE YEAR-END 2020 ESTIMATE TO BE IN RANGE OF $720 - $730 MILLION IN CASH, CASH EQUIVALENTS, RESTRICTED TIME DEPOSITS, INVESTMENTS, RECEIVABLES.  Full Article

Fibrogen Says On July 8, Units And Astrazeneca Entered Into An Amendment To Amended And Restated License, Development And Commercialization Agreement
Saturday, 11 Jul 2020 

July 10 (Reuters) - Fibrogen Inc::FIBROGEN - ON JULY 8, UNITS AND ASTRAZENECA ENTERED INTO AN AMENDMENT TO AMENDED AND RESTATED LICENSE, DEVELOPMENT AND COMMERCIALIZATION AGREEMENT.FIBROGEN - AMENDMENT PROVIDES FOR CREATION OF JOINTLY OWNED ENTITY TO PERFORM ROXADUSTAT DISTRIBUTION, CONDUCT SALES, MARKETING THROUGH ASTRAZENECA.FIBROGEN INC - FIBROGEN BEIJING WILL CONTINUE TO HOLD ALL OF REGULATORY LICENSES ISSUED BY CHINA REGULATORY AUTHORITIES.FIBROGEN - FIBROGEN BEIJING TO CONTINUE TO BE MAINLY RESPONSIBLE FOR REGULATORY, CLINICAL, MANUFACTURING, MEDICAL AFFAIRS, PHARMACOVIGILANCE..FIBROGEN INC - PARTIES WILL CONTINUE TO SHARE EQUALLY IN ECONOMICS RESULTING FROM ROXADUSTAT OPERATIONS IN CHINA.FIBROGEN INC - WITH EFFECT FROM APRIL 1, PARTIES HAVE CHANGED METHOD UNDER WHICH COMMERCIAL EXPENSES ARE BILLED.FIBROGEN - FIBROGEN BEIJING WILL NOW MANUFACTURE & SUPPLY COMMERCIAL PRODUCT TO JV, AT A PERCENTAGE OF NET SALES & SUCH PERCENTAGE WILL BE SUBJECT TO A CAP..FIBROGEN - ASTRAZENECA'S SALES, MARKETING COSTS BILLED TO JV ARE NOW SUBJECT TO ANNUAL CAP AT PERCENTAGE OF NET SALES.FIBROGEN INC - ONCE DISTRIBUTION ENTITY IS FULLY OPERATIONAL, TO RECOGNIZE REVENUE BASED ON ITS SALES TO DISTRIBUTION ENTITY.FIBROGEN INC - ASTRAZENECA IS EXPECTED TO CONSOLIDATE DISTRIBUTION ENTITY, AND RECOGNIZE REVENUE BASED ON SALES TO CUSTOMERS.FIBROGEN INC - DEVELOPMENT COSTS WILL CONTINUE TO BE SHARED 50/50 BETWEEN PARTIES.  Full Article

Fibrogen Says UK High Court Of Justice Has Held Certain Patents Relating To Methods Of Using HIF-PHIs To Be Invalid
Monday, 20 Apr 2020 

April 20 (Reuters) - FibroGen Inc ::FIBROGEN REPORTS UK COURT RULING.FIBROGEN - UK HIGH COURT OF JUSTICE HAS HELD CERTAIN PATENTS RELATING TO METHODS OF USING HIF-PHIS TO BE INVALID.FIBROGEN INC - DECISION DOES NOT AFFECT VALIDITY OF THE CERTAIN PATENTS ACROSS REST OF EUROPE.  Full Article

Fibrogen Inc Signs Agreement For Bulk Manufacture/Supply Of Roxadustat
Wednesday, 25 Mar 2020 

March 24 (Reuters) - FibroGen Inc ::FIBROGEN INC - AGREEMENT WITH SHANGHAI SYNTHEALL PHARMACEUTICAL CO LTD, STA PHARMACEUTICAL HONG KONG LIMITED FOR BULK MANUFACTURE/SUPPLY OF ROXADUSTAT.FIBROGEN INC - MASTER SUPPLY AGREEMENT ALSO FOR OTHER INTERMEDIATES FOR USE IN COMMERCIALIZATION AND DEVELOPMENT OF PRODUCTS CONTAINING ROXADUSTAT.  Full Article

Fibrogen Names Enrique Conterno As Chief Executive Officer
Monday, 6 Jan 2020 

Jan 6 (Reuters) - FibroGen Inc ::FIBROGEN NAMES ENRIQUE CONTERNO AS CHIEF EXECUTIVE OFFICER.FIBROGEN INC - CONTERNO PREVIOUSLY WORKED AS A SENIOR VICE PRESIDENT FOR ELI LILLY AND COMPANY.FIBROGEN - WITH HIRING OF ENRIQUE, JIM SCHOENECK IS APPOINTED CHAIRMAN OF BOARD OF DIRECTORS.  Full Article

FibroCen Reports Q3 Loss Per Share $0.57
Tuesday, 12 Nov 2019 

Nov 11 (Reuters) - FibroGen Inc ::FIBROGEN REPORTS THIRD QUARTER 2019 FINANCIAL RESULTS.Q3 LOSS PER SHARE $0.57.Q3 EARNINGS PER SHARE ESTIMATE $-0.55 -- REFINITIV IBES DATA.AT SEPTEMBER 30, 2019, FIBROGEN HAD $666.5 MILLION IN CASH, RESTRICTED TIME DEPOSITS, CASH EQUIVALENTS, INVESTMENTS, AND RECEIVABLES.AT SEPTEMBER 30, 2019, FIBROGEN HAD $666.5 MILLION IN CASH, RESTRICTED TIME DEPOSITS, CASH EQUIVALENTS, INVESTMENTS, AND RECEIVABLES.  Full Article

Fibrogen Says Evrenzo Approved By Japan’s Ministry of Health, Labour and Welfare
Friday, 20 Sep 2019 

Sept 20 (Reuters) - Fibrogen Inc::FIBROGEN-JAPAN'S MINISTRY OF HEALTH,LABOUR AND WELFARE APPROVED EVRENZO FOR TREATMENT OF ANEMIA RELATED TO CHRONIC KIDNEY DISEASE IN DIALYSIS PATIENTS.  Full Article

FibroGen Reports Q2 Earnings Per Share $1.26
Friday, 9 Aug 2019 

Aug 8 (Reuters) - FibroGen Inc ::FIBROGEN REPORTS SECOND QUARTER 2019 FINANCIAL RESULTS.Q2 EARNINGS PER SHARE $1.26.Q2 EARNINGS PER SHARE ESTIMATE $-0.51 -- REFINITIV IBES DATA.Q2 REVENUE $180 MILLION.Q2 REVENUE ESTIMATE $29 MILLION -- REFINITIV IBES DATA.ON TRACK TO SUBMIT U.S. NDA FOR ROXADUSTAT IN OCTOBER.AT JUNE 30 HAD $686.1 MILLION IN CASH, RESTRICTED TIME DEPOSITS, CASH EQUIVALENTS, INVESTMENTS, AND RECEIVABLES.  Full Article

FibroGen Q1 Loss Per Share $0.53
Friday, 10 May 2019 

May 9 (Reuters) - FibroGen Inc ::FIBROGEN REPORTS FIRST QUARTER 2019 FINANCIAL RESULTS.Q1 LOSS PER SHARE $0.53.Q1 EARNINGS PER SHARE ESTIMATE $-0.67 -- REFINITIV IBES DATA.  Full Article

Fibrogen Inc - Co and Astellas Pharma Inc entered into an amendment to collaboration agreement - SEC Filing
Saturday, 8 Dec 2018 

Dec 7 (Reuters) - Astellas Pharma Inc <4503.T>::FIBROGEN INC SAYS ON NOV 30, CO AND ASTELLAS PHARMA INC. ENTERED INTO AN AMENDMENT TO COLLABORATION AGREEMENT DATED AS OF JUNE 1, 2005 - SEC FILING.FIBROGEN INC - UNDER THIS AMENDMENT, FIBROGEN WOULD CONTINUE TO MANUFACTURE AND DELIVER TO ASTELLAS ROXADUSTAT ACTIVE PHARMACEUTICAL INGREDIENT.FIBROGEN INC - AMENDMENT OBLIGATES ASTELLAS TO PURCHASE A TOTAL OF NET $62.7 MILLION OF ROXADUSTAT ACTIVE PHARMACEUTICAL INGREDIENT.  Full Article

Akebia plunges 73% after anemia treatment fails to meet safety goal

Akebia Therapeutics Inc said on Thursday its experimental drug failed to meet the main safety goal in a late-stage trial testing the treatment in patients with anemia due to chronic kidney disease and not undergoing dialysis.